Groupe RX expands MRI and CT capacity in Toulouse

The investment was split between two Toulouse-area sites run by Groupe RX, or GRX: 3.4 million euros at the Clinique Pasteur in Toulouse and about 3 million euros at the Clinique de L’Union in Saint-Jean. Together, the sites now handle more than 1,000 patients a day with six MRI machines and six scanners, while the group says it has 12 heavy imaging devices in total.

At Pasteur, GRX expanded its imaging unit by 600 square meters and added a third scanner, a third MRI and additional radiography equipment. The works were carried out over 18 months without interrupting activity, a sign of how strongly embedded imaging has become in the clinical flow of large private hospitals. The new configuration has been operating for nearly a year and is due for formal inauguration on Sept. 17.

The bigger economic story is capacity scarcity. French radiology groups have long argued that authorization rules for expensive equipment have been too restrictive, leaving the country short of scanners and MRI machines relative to demand. GRX said the easing of those rules helped make the project viable and reflects a broader catch-up in heavy medical equipment. That matters because imaging is not a discretionary service: it is a bottleneck in oncology, cardiology and emergency care, and every extra machine can unlock additional revenue while reducing queue times.

The group says cardiac imaging waits fell from three to four months to about six weeks, while oncology appointments are now available in about three weeks. In other words, GRX has not just improved service quality; it has increased its addressable volume by reducing lost or deferred demand. For private imaging providers, that is a favorable mix of public health need and private capital discipline.

The L’Union site adds a further MRI, a scanner and a second EOS device for standing spine imaging, broadening the group’s diagnostic mix. The combined GRX network, created in Toulouse in the 1950s, now links 21 physicians and 120 employees across Pasteur and L’Union. The scale matters because imaging groups increasingly compete on utilization rates, referral relationships and speed, not just on equipment count.

For investors in healthcare services and diagnostics, the implication is twofold. First, capital spending on high-throughput imaging remains attractive where backlogs are structural and pricing is relatively resilient. Second, the beneficiary set is not only the imaging operator: hospitals, oncologists and cardiologists gain from faster diagnosis, while patients and payers gain from shorter pathways and fewer repeat visits. The losers are delay-heavy providers and any stakeholders relying on constrained capacity to preserve pricing power.

The risk is that capacity additions can eventually compress margins if equipment utilization fails to keep pace. But in markets where waits are measured in weeks or months, the more immediate issue is undersupply, not oversupply. That makes GRX’s expansion less a cyclical bet than a response to a persistent healthcare infrastructure gap.